2023-08-29 16:50:43 ET
More on FibroGen
- FibroGen, Inc. ( NASDAQ: FGEN ) Q2 2023 Earnings Call Transcript
- FibroGen, Inc. 2023 Q2 - Results - Earnings Call Presentation
- FibroGen's Unsteady Course: Assessing Fallout From IPF Failure And The Road Ahead
- FibroGen: Several Pamrevlumab Data Releases Could Change Scope Of Biotech
- BofA downgrades FibroGen to underperform, cites unfavorable catalysts
- FibroGen to cut 32% of U.S. workforce in restructuring plan
- Stifel downgrades FibroGen to hold, says it's lost confidence in lead drug
- Biggest stock movers today: Pfizer, FibroGen, Lucid and more
- Seeking Alpha’s Quant Rating on FibroGen
- Earnings data for FibroGen
For further details see:
FibroGen stock tumbles on failed Phase 3 study for muscular dystrophy drug